Ibrutinib

In this video, Michael Choi, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.

CHICAGO — The addition of venetoclax to ibrutinib and obinutuzumab did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting.

Janssen and Pharmacyclics intend to voluntarily withdraw the U.S. indications of ibrutinib for certain patients with lymphoma, according to a press release.

Chronic graft-versus-host disease continues to be a leading cause of late morbidity and mortality, complicating approximately 35% to 50% of allogeneic transplantations.

The FDA approved zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.

NEW ORLEANS — Patients with newly diagnosed mantle cell lymphoma who received ibrutinib with a standard-of-care regimen had higher failure-free survival rates than those who received standard-of-care treatment alone.

The FDA approved ibrutinib for children with chronic graft-versus-host disease.

CHICAGO — A novel first-line regimen significantly improved PFS compared with standard chemoimmunotherapy for older patients with mantle cell lymphoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.

SALT LAKE CITY — Ibrutinib appeared safe and effective for children with previously untreated or relapsed/refractory chronic graft-versus-host disease, according to study results.